Edward Kelly to Renal Insufficiency, Chronic
This is a "connection" page, showing publications Edward Kelly has written about Renal Insufficiency, Chronic.
Connection Strength
1.201
-
Tsang YP, Aryeh KS, Wang K, Himmelfarb J, Yeung CK, Kelly EJ. Enhancing therapeutic strategies and drug development for patients with kidney disease. Expert Opin Drug Saf. 2026 Jan; 25(1):23-48.
Score: 0.827
-
Chang SY, Huang W, Chapron A, Qui?ones AJL, Wang J, Isoherranen N, Shen DD, Kelly EJ, Himmelfarb J, Yeung CK. Incorporating Uremic Solute-mediated Inhibition of OAT1/3 Improves PBPK Prediction of Tenofovir Renal and Systemic Disposition in Patients with Severe Kidney Disease. Pharm Res. 2023 Nov; 40(11):2597-2606.
Score: 0.182
-
Imaoka T, Huang W, Shum S, Hailey DW, Chang SY, Chapron A, Yeung CK, Himmelfarb J, Isoherranen N, Kelly EJ. Bridging the gap between in silico and in vivo by modeling opioid disposition in a kidney proximal tubule microphysiological system. Sci Rep. 2021 11 01; 11(1):21356.
Score: 0.160
-
Chang SY, Weber EJ, Sidorenko VS, Chapron A, Yeung CK, Gao C, Mao Q, Shen D, Wang J, Rosenquist TA, Dickman KG, Neumann T, Grollman AP, Kelly EJ, Himmelfarb J, Eaton DL. Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight. 2017 11 16; 2(22).
Score: 0.030